Abstract
Background There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. Methods Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 13 Italian institutions. Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with logrank test. The association of clinicopathological variables and the outcome was studied by binary logistic regression analysis and Cox proportional hazard analysis. Results At a median follow-up of 41 months, median PFS and OS were 7 and 21 months, respectively. Patents with a PFS longer than 7 months had a significantly longer OS, compared with patients with a PFS equal to or shorter than 7 months (36 vs 15 months; p
| Original language | English |
|---|---|
| Article number | e0156221 |
| Journal | PLoS One |
| Volume | 11 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - May 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer : Results from the italian retrospective multicenter HERLAPAC study. / Gori, Stefania; Inno, Alessandro; Rossi, Valentina; Turazza, Monica; Fiorio, Elena; Fabi, Alessandra; Bisagni, Giancarlo; Foglietta, Jennifer; Santini, Daniele; Pavese, Ida; Pellegrino, Arianna; Zambelli, A.; Vici, Patrizia; Leonardi, Vita; Barni, Sandro; Saracchini, S.; Bogina, Giuseppe; Marchetti, Fabiana; Duranti, Simona; Lunardi, Gianluigi; Montemurro, Filippo.
In: PLoS One, Vol. 11, No. 5, e0156221, 01.05.2016.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Predictive factors of lapatinib and capecitabine activity in patients with HER2-positive, trastuzumab-resistant metastatic breast cancer
T2 - Results from the italian retrospective multicenter HERLAPAC study
AU - Gori, Stefania
AU - Inno, Alessandro
AU - Rossi, Valentina
AU - Turazza, Monica
AU - Fiorio, Elena
AU - Fabi, Alessandra
AU - Bisagni, Giancarlo
AU - Foglietta, Jennifer
AU - Santini, Daniele
AU - Pavese, Ida
AU - Pellegrino, Arianna
AU - Zambelli, A.
AU - Vici, Patrizia
AU - Leonardi, Vita
AU - Barni, Sandro
AU - Saracchini, S.
AU - Bogina, Giuseppe
AU - Marchetti, Fabiana
AU - Duranti, Simona
AU - Lunardi, Gianluigi
AU - Montemurro, Filippo
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Background There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. Methods Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 13 Italian institutions. Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with logrank test. The association of clinicopathological variables and the outcome was studied by binary logistic regression analysis and Cox proportional hazard analysis. Results At a median follow-up of 41 months, median PFS and OS were 7 and 21 months, respectively. Patents with a PFS longer than 7 months had a significantly longer OS, compared with patients with a PFS equal to or shorter than 7 months (36 vs 15 months; p
AB - Background There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. Methods Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 13 Italian institutions. Estimates of progression-free survival (PFS) and overall survival (OS) were obtained with the Kaplan-Meier method and compared with logrank test. The association of clinicopathological variables and the outcome was studied by binary logistic regression analysis and Cox proportional hazard analysis. Results At a median follow-up of 41 months, median PFS and OS were 7 and 21 months, respectively. Patents with a PFS longer than 7 months had a significantly longer OS, compared with patients with a PFS equal to or shorter than 7 months (36 vs 15 months; p
UR - http://www.scopus.com/inward/record.url?scp=84971450036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84971450036&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0156221
DO - 10.1371/journal.pone.0156221
M3 - Article
VL - 11
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 5
M1 - e0156221
ER -